Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]SKLB1028 in Healthy Chinese Males
NCT05369858Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruserontinib in acute myeloid leukemia (AML), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum Plasma Concentration (Cmax) at 144 hours, Time to Maximum Plasma Concentration (Tmax) at 144 hours and 3 more. Started Aug 2021; status: completed.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05369858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369858.